SCHEDULE 13G/A: Rosalind Advisors and Affiliates Update Passive Stake in Trevi Therapeutics to 1.21%

Rosalind Advisors, Inc., Rosalind Master Fund L.P., and associated individuals have filed an amendment to their Schedule 13G, disclosing a passive beneficial ownership of 1.21% in Trevi Therapeutics, Inc.'s common shares.

Summary

• Rosalind Advisors, Inc., Rosalind Master Fund L.P., Steven Salamon, and Gilad Aharon collectively reported beneficial ownership of 1,062,500 common shares of Trevi Therapeutics, Inc.
• This ownership represents 1.21% of Trevi Therapeutics' common stock outstanding.
• The percentage is based on 87,954,375 shares of common stock outstanding as of December 13, 2024, as reported in a 424B5 filing.
• All reporting persons share both voting and dispositive power over the 1,062,500 shares.
• The filing is an Amendment No. 4 to Schedule 13G, indicating previous filings by these parties.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing (Schedule 13G/A) disclosing passive beneficial ownership. It contains factual information about ownership percentages and does not convey positive or negative sentiment regarding the company's performance or outlook.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Trevi Therapeutics, Inc.'s future performance or operations.

Management Comments

• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11."

Industry Context

This filing is a routine disclosure of passive beneficial ownership by an investment firm and its affiliates in a publicly traded biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the ownership stake itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding the ownership structure and significant passive holders, confirming that Rosalind's stake is not intended to influence control.

Key Dates

Keywords

Trevi Therapeutics, Rosalind Advisors, Rosalind Master Fund, Schedule 13G/A, Beneficial Ownership, Common Shares, SEC Filing, Investment Fund, Passive Investment